AstraZeneca Korea boosts efforts for IPC recertification, emphasizing R&D and innovation
AstraZeneca Korea, a subsidiary of the global biopharmaceutical giant, is intensifying its efforts to secure recertification as an Innovative Pharmaceutical Company (IPC) by the end of this year. The IPC certification, valid for three years, is designated …